EA201200241A1 - Новая кристаллическая форма органического соединения и способ её получения - Google Patents

Новая кристаллическая форма органического соединения и способ её получения

Info

Publication number
EA201200241A1
EA201200241A1 EA201200241A EA201200241A EA201200241A1 EA 201200241 A1 EA201200241 A1 EA 201200241A1 EA 201200241 A EA201200241 A EA 201200241A EA 201200241 A EA201200241 A EA 201200241A EA 201200241 A1 EA201200241 A1 EA 201200241A1
Authority
EA
Eurasian Patent Office
Prior art keywords
obtaining
organic compounds
crystal form
new crystal
norpregna
Prior art date
Application number
EA201200241A
Other languages
English (en)
Other versions
EA019114B1 (ru
Inventor
Аттила Балаж
Янош Чёргей
Адам Деметер
Чаба Санта
Original Assignee
Рихтер Гедеон Нирт.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Рихтер Гедеон Нирт. filed Critical Рихтер Гедеон Нирт.
Publication of EA201200241A1 publication Critical patent/EA201200241A1/ru
Publication of EA019114B1 publication Critical patent/EA019114B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к новой кристаллической форме II 17α-ацетокси-21-метокси-11β-[4-N,N-диметиламинофенил]-19-норпрегна-4,9-диен-3,20-диона (также известного как CDB-4124), способам её получения и содержащей её фармацевтической композиции. Форма II может быть получена кристаллизацией из различных сред, например из сложных эфиров C-C-спиртов и карбоновых кислот, кетонов, циклогексана, ацетонитрила, диметилформамида, диметилсульфоксида, воды и их смесей.
EA201200241A 2009-08-05 2010-08-05 НОВАЯ КРИСТАЛЛИЧЕСКАЯ ФОРМА 17α-АЦЕТОКСИ-21-МЕТОКСИ-11β-[4-N,N-ДИМЕТИЛАМИНОФЕНИЛ]-19-НОРПРЕГНА-4,9-ДИЕН-3,20-ДИОНА И СПОСОБ ЕЁ ПОЛУЧЕНИЯ EA019114B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0900487A HUP0900487A2 (hu) 2009-08-05 2009-08-05 17-acetoxi-11ß-[4-(dimetil-amino)-fenil]-21-metoxi-19-norpregna-4,9-dién-3,20-dion új kristályos polimorf módosulata és eljárás elõállítására
PCT/HU2010/000088 WO2011015892A2 (en) 2009-08-05 2010-08-05 Novel crystal form of an organic compound and process for the preparation thereof

Publications (2)

Publication Number Publication Date
EA201200241A1 true EA201200241A1 (ru) 2012-07-30
EA019114B1 EA019114B1 (ru) 2014-01-30

Family

ID=89989159

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200241A EA019114B1 (ru) 2009-08-05 2010-08-05 НОВАЯ КРИСТАЛЛИЧЕСКАЯ ФОРМА 17α-АЦЕТОКСИ-21-МЕТОКСИ-11β-[4-N,N-ДИМЕТИЛАМИНОФЕНИЛ]-19-НОРПРЕГНА-4,9-ДИЕН-3,20-ДИОНА И СПОСОБ ЕЁ ПОЛУЧЕНИЯ

Country Status (7)

Country Link
US (2) US9221870B2 (ru)
EP (1) EP2462154B1 (ru)
EA (1) EA019114B1 (ru)
ES (1) ES2546098T3 (ru)
HU (2) HUP0900487A2 (ru)
PL (1) PL2462154T3 (ru)
WO (1) WO2011015892A2 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0900171A2 (hu) 2009-03-20 2010-12-28 Richter Gedeon Nyrt 17-acetoxi-11ß-[4-(dimetil-amino)-fenil]-21-metoxi-19-norpregna-4,9-dién-3,20-dion új kristályos módosulata és eljárás elõállítására

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3921059A1 (de) * 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
DE4042007A1 (de) * 1990-12-22 1992-06-25 Schering Ag 6,7-modifizierte-11(beta)-aryl-4-estrene
CA2253673C (en) * 1996-05-01 2009-09-08 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
DE60021422T2 (de) 1999-12-29 2006-05-24 The Government of the United States of America, as represented by the Secretary National Institute of Health, Office of Technology Transfer Verfahren zur Herstellung von 17α-acetoxy-11β-[4-n,n-(dimethylamino)phenyl]-21-methoxy-19-norpregna-4,9-dien-3,20-dion, für das Verfahren nützliche Zwischenprodukte und Verfahren zur Herstellung derartiger Zwischenprodukte
ES2546291T3 (es) 2000-03-17 2015-09-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services 17-Alfa-sustituida, 11-beta-sustituida-4-arilo y 21-sustituida 19-norpregnadienodionas como agentes antiprogestacionales
US8044223B2 (en) 2003-04-04 2011-10-25 Bridge Organics Co. Crystalline 19-norsteroids
WO2007103510A2 (en) * 2006-03-08 2007-09-13 Danco Laboratories Llc Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
KR20090105944A (ko) 2007-01-17 2009-10-07 레프로스 쎄라피우틱스 아이엔씨. 11-(4-아미노페닐)-19-노르프레그나-4,9(10)-디엔-3,20-디온 유도체의 약학적으로 허용가능한 염
HU228636B1 (en) * 2007-06-27 2013-04-29 Richter Gedeon Nyrt Industrial method for the synthesis of 17-acetoxy-11betha-4[-(dimethylamino)-phenyl]-21-methoxy-19-norpregna-4,9-dien-3,20-dione and the key intermediates of the process
TW201002736A (en) 2008-04-28 2010-01-16 Repros Therapeutics Inc Compositions and methods for treating progesterone-dependent conditions
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
HUP0900171A2 (hu) 2009-03-20 2010-12-28 Richter Gedeon Nyrt 17-acetoxi-11ß-[4-(dimetil-amino)-fenil]-21-metoxi-19-norpregna-4,9-dién-3,20-dion új kristályos módosulata és eljárás elõállítására

Also Published As

Publication number Publication date
ES2546098T3 (es) 2015-09-18
HUE025397T2 (en) 2016-02-29
WO2011015892A2 (en) 2011-02-10
PL2462154T3 (pl) 2015-12-31
US20160220585A1 (en) 2016-08-04
HUP0900487A2 (hu) 2011-03-28
US9221870B2 (en) 2015-12-29
US20120142655A1 (en) 2012-06-07
WO2011015892A3 (en) 2011-03-31
HU0900487D0 (en) 2009-09-28
EP2462154A2 (en) 2012-06-13
EP2462154B1 (en) 2015-06-24
EA019114B1 (ru) 2014-01-30

Similar Documents

Publication Publication Date Title
AU2018250355B2 (en) Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
DK2562262T3 (da) Fremgangsmåde til fremstilling af ethanol fra to-tre forskellige udgangsmaterialer
EA201200716A1 (ru) Способ получения кристаллических форм а и в илапразола и способ превращения указанных кристаллических форм
PL394857A1 (pl) Sposób amonotermalnego wytwarzania kryształów ciągnionych azotku galu na dużą skalę
EA201200117A1 (ru) Способ получения водной суспензии органического пестицидного соединения
DK1910267T3 (da) Fremgangsmåde til fremstilling af carboxylsyrealkylestere
EP2611764A4 (en) FERMENTATION ROUTE FOR THE PRODUCTION OF LÉVULINIC ACID, LEVULINATE ESTERS, VALÉROLACTONE, AND CERTAIN OF THEIR DERIVATIVES
HK1169647A1 (en) Process for the production of ethanol by hydrogenation of vaporized acetic acid
IL217509A0 (en) Process for producing crystals of polymorphic 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid by poor-solvent addition method
AR081659A1 (es) Procedimiento de obtencion de la forma cristalina ii del febuxostat
MX2020011330A (es) Proceso para la preparacion de la forma 1 del propionato de fluticasona.
WO2010036638A3 (en) Compounds for the treatment of inflammatory disorders
WO2012158861A3 (en) Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives
WO2012112841A3 (en) [1,2,4]oxadiazol-3-yl acid salts and crystalline forms and their preparation
WO2013153492A3 (en) Process for the preparation of vilazodone hydrochloride and its amorphous form
EA201200241A1 (ru) Новая кристаллическая форма органического соединения и способ её получения
WO2010036640A3 (en) Compounds for the treatment of inflammatory disorders
WO2012115402A3 (en) Crystalline form of docetaxel and process for preparation thereof
FR2974945B1 (fr) Procede de cristallisation orientee de materiaux
WO2011118929A3 (en) Novel crystal forms of epirubicin hydrochloride
FR2941959B1 (fr) Procedes de production d'acide succinique
WO2015084693A3 (en) New process for preparing loratadine from a ketone intermediate
WO2010086700A3 (en) An improved process for the preparation of choline salt of fenofibric acid and its novel polymorph
WO2013046233A3 (en) Process for the preparation of octreotide acetate
DK2585182T3 (da) Fremgangsmåde til fremstilling af farmakologisk rene krystaller

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU